Provided by Tiger Trade Technology Pte. Ltd.

ProQR Therapeutics NV

1.88
-0.0642-3.31%
Volume:354.22K
Turnover:673.13K
Market Cap:264.71M
PE:-4.10
High:1.98
Open:1.97
Low:1.87
Close:1.94
52wk High:3.10
52wk Low:1.33
Shares:141.12M
Float Shares:101.18M
Volume Ratio:1.07
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4578
EPS(LYR):-0.4702
ROE:-57.40%
ROA:-19.76%
PB:2.87
PE(LYR):-3.99

Loading ...

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment

MT Newswires Live
·
Sep 09

ProQR Therapeutics doses first participant in AX-0811 clinical trial

TIPRANKS
·
Sep 09

ProQR Announces First Participant Dosed in Phase 1 Study of Ax-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

THOMSON REUTERS
·
Sep 09

ProQR Therapeutics Held Annual Shareholder Meeting in Amsterdam

Reuters
·
Sep 01

ProQR Therapeutics (PRQR) Stock Rises On Revenue Surge As Losses Ease

Simply Wall St.
·
Aug 15

Cantor Fitzgerald Keeps Their Buy Rating on ProQR (PRQR)

TIPRANKS
·
Aug 14

ProQR Therapeutics NV Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

ProQR Q2 Revenue More than Doubles

Reuters
·
Aug 13

ProQR Q2 FY26 Net Loss Narrows to EUR 8.7 Million

Reuters
·
Aug 13

ProQR Therapeutics Q2 Basic EPS EUR -0.08

THOMSON REUTERS
·
Aug 13

ProQR Therapeutics Q2 Revenue EUR 8.759 Million VS. Ibes Estimate EUR 4.58 Million

THOMSON REUTERS
·
Aug 13

ProQR Therapeutics NV Expected to Post a Loss of 11 Cents a Share - Earnings Preview

Reuters
·
Aug 11

ProQR CEO Daniel Anton De Boer Acquires 200,000 Shares for $353,960

Reuters
·
Aug 04

ProQR Therapeutics NV Expected to Post a Loss of 11 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Proqr Therapeutics Director Bart Filius Buys $257,925 of Common Shares

Reuters
·
Jul 21

Proqr CEO Daniel Anton De Boer Buys 150,000 Shares for $261,000

Reuters
·
Jul 13

Proqr CEO Daniel Anton De Boer Buys $238,500 in Ordinary Shares

Reuters
·
Jul 09

ProQR Registers Shares for Resale by Investor

MT Newswires Live
·
Jul 07

Proqr Therapeutics Nv - Files to Register Resale of up to 3.03 Mln Ordinary Shares - SEC Filing

THOMSON REUTERS
·
Jul 07

Oppenheimer Reaffirms Their Buy Rating on ProQR (PRQR)

TIPRANKS
·
Jul 06